Table 2

Average BCVA, CCT and ECD during the follow-up period in the graft viral DNA+ group and the control group

Last time of follow-upAverage ECD during follow-up period (cells/mm2)
BCVACCT (μm)6 months12 months24 months
Total
 Graft viral DNA+ (n=25)0.71±0.70605±1212290±4812052±4911716±476
 Control (n=48)0.70±0.62590±792547±4302363±3722156±369
PK
 Graft viral DNA+ (n=9)1.01±0.83593±972232±3781942±4391442±291
 Control (n=16)0.95±0.62587±442576±2962320±2052038±166
DASEK
 Graft viral DNA+ (n=9)0.54±0.34667±1562336±5122026±4581659±366
 Control (n=18)0.59±0.50631±992656±4002471±3312230±385
DALK
 Graft viral DNA+ (n=7)0.54±0.81541±812305±5452230±5432140±497
 Control (n=14)0.55±0.72541±512375±5302274±5112198±469
HSV-1
 Graft viral DNA+ (n=4)0.88±1.04607±642374±4092059±3991588±211
 Control (n=7)0.77±0.78598±542571±3912320±1352066±115
CMV
 Graft viral DNA+ (n=7)0.96±0.73606±1112113±3291797±2671486±322
 Control (n=15)0.93±0.66611±862550±2952343±2642079±282
VZV
 Graft viral DNA+ (n=5)0.50±0.14637±1322266±5651995±5931427±341
 Control (n=8)0.54±0.16616±1102651±3042468±3262203±362
EBV
 Graft viral DNA+ (n=2)0.65±0.49642±622750±402460±1392012±280
 Control (n=4)0.57±0.33616±332893±4562616±3492366±434
  • The average ECD of grafts for HSV-1, CMV, VZV and EBV DNA does not include the data of recipients who underwent DALK.

  • BCVA, best-corrected visual acuity; CCT, central corneal thickness; CMV, cytomegalovirus; DALK, deep lamellar keratoplasty; ECD, endothelial cell density; EBV, Epstein–Barr virus; HSV, herpes simplex virus; PK, penetrating keratoplasty; VZV, varicella-zoster virus